Nova Eye Medical Ltd
ASX:EYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nova Eye Medical Ltd
Net Change in Cash
Nova Eye Medical Ltd
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nova Eye Medical Ltd
ASX:EYE
|
Net Change in Cash
-AU$1.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Net Change in Cash
-AU$469.9k
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
11%
|
|
|
Cochlear Ltd
ASX:COH
|
Net Change in Cash
-AU$196m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Net Change in Cash
AU$10.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
100%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Net Change in Cash
AU$5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Net Change in Cash
AU$3.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Nova Eye Medical Ltd
Glance View
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).
See Also
What is Nova Eye Medical Ltd's Net Change in Cash?
Net Change in Cash
-1.1m
AUD
Based on the financial report for Dec 31, 2025, Nova Eye Medical Ltd's Net Change in Cash amounts to -1.1m AUD.
What is Nova Eye Medical Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
53%
Over the last year, the Net Change in Cash growth was -210%. The average annual Net Change in Cash growth rates for Nova Eye Medical Ltd have been 53% over the past three years .
